Biologics for Nasal Polyps: A New Era Without Surgery?

For years, patients with severe nasal polyps have been trapped in a frustrating, seemingly endless cycle: undergo sinus surgery, experience a brief period of relief, and then watch in despair as the polyps grow back, destroying their sense of smell and blocking their airway all over again. In my opinion, the introduction of targeted biologic therapies is the single greatest breakthrough in the field of rhinology over the last two decades. We are finally moving away from simply cutting out the disease, and instead, we are turning it off at the cellular level.

To understand why Biologics are so revolutionary, we must understand why polyps recur. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is rarely just a localized physical blockage. In the vast majority of severe cases, it is driven by a systemic immune system dysfunction known as Type 2 Inflammation. Your immune system acts as if it is constantly under attack, flooding the nasal mucosal lining with eosinophils (specialized white blood cells) and inflammatory proteins called interleukins. This biological "switch" is stuck in the active position, relentlessly driving the growth of polypoid tissue. Traditional surgery removes the polyps, but it does not turn off the switch.

Biologics are the "off-switch." These medications are highly advanced monoclonal antibodies, administered via subcutaneous injection, designed to intercept and neutralize the specific interleukins causing the inflammation.

Here is how we deploy these precision-medicine tools:

• Targeting IL-4 and IL-13: Medications like Dupilumab specifically bind to the receptors for Interleukin-4 and Interleukin-13. By blocking these critical inflammatory pathways, we see massive, rapid shrinkage of the polyp burden.

• Targeting IL-5: Medications like Mepolizumab target Interleukin-5, which is the primary survival factor for eosinophils. By neutralizing IL-5, we starve the polyps of the cells that cause them to swell.

• Targeting IgE: For patients whose polyps are heavily driven by severe allergies and asthma, medications like Omalizumab bind directly to Immunoglobulin E (IgE), preventing the allergic cascade from initiating in the nose.

The clinical results from trials are promising. Patients who start biologic therapy not only experience dramatic reductions in polyp size, but they frequently report a profound, rapid return of their sense of smell (anosmia reversal)—something that even surgery sometimes struggles to guarantee. Most importantly, biologics safely break the cycle of recurrence, keeping patients out of the operating room.

Biologics are not necessary for a first-time, mild polyp patient. However, if you have recalcitrant polyps, co-existing asthma, or have already failed previous sinus surgeries, you no longer have to accept a life of endless operations. Precision medicine has finally arrived for sinus disease.

References:

1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet. 2019;394(10209):1638-1650.

2. Fokkens WJ, Viskens AS, Backer V, et al. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology. 2023;61(3):194-202.

Wirach Chitsuthipakorn, MD
Rhinologist-Sinus surgeon.
return to articles